Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine

Palliative Medicine

Volumn 14, Issue 2, 2000, Pages 111-119

  Radbruch, Lukas ^b   Sabatowski, Rainer ^c   Loick, Georg ^c   Kulbe, Carsten ^a   Kasper, Mario ^b   Grond, Stefan ^b   Lehmann, Klaus A ^b  

^a Center of Psychiatry and Psychotherapeutic Medicine   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Universität zu Köln ^*

Author keywords

Administration, cutaneous; Analgesics, opioid; Cathartics; Constipation; Fentanyl; Morphine

Indexed keywords

FENTANYL; LACTULOSE; LAXATIVE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; FEMALE; HUMAN; MALE; MULTICENTER STUDY; SLOW RELEASE FORMULATION;

EID: 0034085318     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/026921600671594561     Document Type: Article

References (18)

1. Hanks GW, DeConno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. Br Med J 1996; 312: 823-26.
2. World Health Organization. Cancer pain relief. Geneva: World Health Organization, 1986.
3. World Health Organization. Cancer pain relief: with a guide to opioid availability, 2nd edn. Geneva: World Health Organization, 1996.
4. Megens AA, Artois K, Vermeire J, Meert T, Awouters FH. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Sympt Manage 1998; 15: 253-58.
5. Herz A, Teschemacher HJ. Activities and sites of antinociceptive action of morphine-like analgesics and kinetics of distribution following intravenous, intracerebral and intraventricular application. Adv Drug Res 1971; 6: 79-119.
6. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13: 254-61.
7. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64: 527-34.
8. Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997; 69: 1-8.
9. Aaronson NK, Ahmedzai S, Bergmann B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
10. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-38.
11. Ahmedzai S, Allan E, Fallon M et al. Transdermal fentanyl in cancer pain. J Drug Dev 1994; 6: 93-97.
12. Sloan PA, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998; 16: 102-11.
13. Slappendel R, Lako SJ, Crul BJ. Gastrointestinal side effects diminish after switch over from morphine to transdermal fentanyl. Ann Oncol 1994; 5: 200.
14. Slover R. Transdermal fentanyl: clinical trial at the University of Colorado Health Sciences Center. J Pain Symptom Manage 1992; 7: S45-47.
15. Zech DF, Grond SU, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992; 50: 293-301.
16. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 1998; 2: 53-62.
17. Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiolog Sin 1997; 35: 25-32.
18. Sykes NP. Constipation and diarrhoea. In: Doyle D, Hanks G, MacDonald M eds. Oxford textbook of palliative medicine, 2nd edn. Oxford: Oxford University Press, 1998: 513-26.